Beyondspring Inc (BYSI)

• $2.30

  $2.42

  $2.37
  

  2.95%

  Downside

  Day's Volatility :4.96%

  Upside

  2.07%

  
• $0.78

  $4.00

  $2.37
  

  67.19%

  Downside

  52 Weeks Volatility :80.56%

  Upside

  40.75%

  

Returns

What analysts predicted

Downside of 47.26%

• Decheng Capital LLC

  12.30%

• Citigroup Inc

  1.13%

• BlackRock Inc

  0.53%

• Tanaka Capital Management Inc

  0.07%

• Geode Capital Management, LLC

  0.06%

• UBS Group AG

  0.04%

beyondspring pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. we are currently advancing the development of our lead asset plinabulin, a novel cancer therapeutic, in a global phase 3 trial in non-small-cell lung cancer (nsclc) and initiating a pivotal global phase 3 trial in prevention of docetaxel-induced neutropenia. as a tubulin depolymerizing agent, plinabulin works via multiple mechanisms of action to target and alter the tumor microenvironment: 1. immune enhancing effects via dendritic cell maturation 2. tumor cell apoptosis via activation of ras-jnk pathway 3. vascular disruptive effects given plinabulin’s potential as a tumor micro-environment targeting agent, we intend to initiate clinical trials in additional cancer indications: • immuno-oncology, with immune checkpoint inhibitors in nsclc • cns malignancies including glioblastoma (gbm) • kras positive mutant cancers